Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2016 (2016), Article ID 6020691, 5 pages
http://dx.doi.org/10.1155/2016/6020691
Case Report

Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma

1Cardiology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
2Hematology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
3Vascular Medicine and Hemostasis, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
4Pathology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
5Nephrology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium

Received 28 February 2016; Accepted 28 April 2016

Academic Editor: Marie-Christine Kyrtsonis

Copyright © 2016 Jan Van Keer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. L. Moake, “Thrombotic microangiopathies,” The New England Journal of Medicine, vol. 347, no. 8, pp. 589–600, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Morita, S. Hashino, S. Shirai et al., “Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma,” International Journal of Hematology, vol. 88, no. 2, pp. 248–250, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Moore and K. Romeril, “Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib,” Internal Medicine Journal, vol. 41, no. 4, pp. 348–350, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. U. Salmenniemi and K. Remes, “Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma,” Hematology Reports, vol. 4, no. 2, article e13, 2012. View at Google Scholar
  5. N. Mehta, A. Saxena, and R. Niesvizky, “Bortezomib-induced thrombotic thrombocytopaenic purpura,” BMJ Case Reports, 2012. View at Publisher · View at Google Scholar
  6. K.-L. Chan, R. Filshie, H. Nandurkar, and H. Quach, “Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma,” Leukemia and Lymphoma, vol. 56, no. 7, pp. 2185–2186, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Jagannath, B. Barlogie, J. Berenson et al., “A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma,” British Journal of Haematology, vol. 127, no. 2, pp. 165–172, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. P. G. Richardson, B. Barlogie, J. Berenson et al., “A phase 2 study of bortezomib in relapsed, refractory myeloma,” The New England Journal of Medicine, vol. 348, no. 26, pp. 2609–2617, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Shortt, D. H. Oh, and S. S. Opat, “ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura,” The New England Journal of Medicine, vol. 368, no. 1, pp. 90–92, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. M. R. Sullivan, A. V. Danilov, F. Lansigan, and N. M. Dunbar, “Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange,” Journal of Clinical Apheresis, vol. 30, no. 5, pp. 308–310, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Hobeika, S. E. Self, and J. C. Q. Velez, “Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma,” BMC Nephrology, vol. 15, no. 1, article 156, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Lodhi, A. Kumar, M. U. Saqlain, and M. Suneja, “Thrombotic microangiopathy associated with proteasome inhibitors,” Clinical Kidney Journal, vol. 8, no. 5, pp. 632–636, 2015. View at Publisher · View at Google Scholar
  13. I. R. Edwards and J. K. Aronson, “Adverse drug reactions: definitions, diagnosis, and management,” The Lancet, vol. 356, no. 9237, pp. 1255–1259, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Kojouri, S. K. Vesely, and J. N. George, “Quinine-associated thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes,” Annals of Internal Medicine, vol. 135, no. 12, pp. 1047–1051, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Huynh, K. Chee, and D. H. M. Lau, “Thrombotic thrombocytopenic purpura associated with quetiapine,” Annals of Pharmacotherapy, vol. 39, no. 7-8, pp. 1346–1348, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. M. W. Saif, V. Xyla, N. Makrilia, I. Bliziotis, and K. Syrigos, “Thrombotic microangiopathy associated with gemcitabine: rare but real,” Expert Opinion on Drug Safety, vol. 8, no. 3, pp. 257–260, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. J. N. George and C. M. Nester, “Syndromes of thrombotic microangiopathy,” The New England Journal of Medicine, vol. 371, no. 7, pp. 654–666, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Zhu, S. Wu, W. L. Dahut, and C. R. Parikh, “Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis,” American Journal of Kidney Diseases, vol. 49, no. 2, pp. 186–193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. V. Eremina, J. A. Jefferson, J. Kowalewska et al., “VEGF inhibition and renal thrombotic microangiopathy,” The New England Journal of Medicine, vol. 358, no. 11, pp. 1129–1136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. M. Roccaro, T. Hideshima, N. Raje et al., “Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells,” Cancer Research, vol. 66, no. 1, pp. 184–191, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Tamura, T. Arao, K. Tanaka et al., “Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition,” Cancer Science, vol. 101, no. 6, pp. 1403–1408, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Stangl and V. Stangl, “The ubiquitin-proteasome pathway and endothelial (dys)function,” Cardiovascular Research, vol. 85, no. 2, pp. 281–290, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Lechner and H. L. Obermeier, “Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases,” Medicine, vol. 91, no. 4, pp. 195–205, 2012. View at Publisher · View at Google Scholar · View at Scopus